Pavella Therapeutics Inc. (PVLA)
Summary
Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish
Palvella Therapeutics is now a much more credible bet on QTORIN after their positive mLM data. They've also received some FDA feedback, which bodes well for their upcoming NDA submission. PVLA is now targeting a 2H2026 NDA submission for QTORIN rapamycin in mLM.
Palvella Therapeutics Q1 Earnings Call Highlights
Palvella Therapeutics NASDAQ: PVLA said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microcystic Lymphatic Malformations, after reporting what executives described as positive Phase 3 results and outlining an expanded commercial plan supported by a recent $230 million financing.
Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript
Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript
Pavella Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 2 | $209 | $307.45 | $98.45 | 47.11% |
| BG Bart Gancher Intech Investment Management LLC | 1,974 | $123,750.06 | $300,107.22 | $176,357.16 | 142.51% |
 Point72 Asset Management LP Point72 Asset Management LP | 88,160 | $6.2M | $13.41M | $7.21M | 116.25% |
 Jeff Ameen Spire Wealth Management | 1,000 | $27,990 | $149,680 | $121,690 | 434.76% |
 Joseph Castro Nuveen LLC | 20,834 | $1.31M | $3.2M | $1.88M | 143.09% |
Pavella Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Geulah Livshits Chardan Capital | 98.94 | $14,664.39 | $15,036.41 | $372.02 | 2.54% |
Pavella Therapeutics Inc. (PVLA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pavella Therapeutics Inc. ever had a stock split?
Pavella Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Wesley H. Kaupinen CEO | NASDAQ (CM) Exchange | 697947109 CUSIP |
| US Country | 29 Employees | - Last Dividend | 23 Apr 2024 Last Split | - IPO Date |
Overview
Pavella Therapeutics Inc. stands as a beacon of innovation within the biotechnology industry, dedicated to revolutionizing the treatment landscape for rare genetic disorders. This groundbreaking company distinguishes itself by focusing on the research and development of novel therapies aimed at addressing the plethora of unmet medical needs within the realm of genetic diseases. By harnessing the power of advanced biotechnological innovations, Pavella Therapeutics Inc. is not just a participant in the healthcare and pharmaceutical sectors but a trailblazer, advocating for precision medicine approaches and the creation of personalized therapies. Their mission is to scout the horizons of medical science, identifying and tackling niche areas often disregarded by the pharmaceutical giants. This singular focus allows them to offer a glimmer of hope and viable treatment avenues to patients who previously faced a future with sparse options. In the financial markets, their distinctive stance and pioneering efforts in specialized domains underscore their potential to effectuate profound impacts, enhancing the overall biotechnology landscape by deepening our understanding of genetic conditions and championing the development of targeted biotherapeutic solutions.
Products and Services
- Innovative Therapies for Rare Genetic Disorders
Pavella Therapeutics is at the forefront of developing cutting-edge treatments specifically designed to combat rare genetic disorders. Their research initiatives are geared towards creating therapies that are not only effective but also tailored to meet the individual needs of patients. This ensures a personalized treatment approach, greatly enhancing the chances of success and improving the quality of life for those affected.
- Advanced Biotechnological Innovations
At the core of Pavella Therapeutics' operations lies a commitment to biotechnological advancements. Through relentless pursuit of innovation, the company continually explores and adopts new technologies and methodologies. These efforts are aimed at advancing their capability to understand, diagnose, and treat genetic diseases more precisely. By doing so, Pavella Therapeutics remains a key player in pushing the boundaries of what is possible in the treatment of rare genetic conditions.
